SanofiSNY
SNY
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
27% more call options, than puts
Call options by funds: $94.5M | Put options by funds: $74.6M
1.48% less ownership
Funds ownership: 22.39% [Q3] → 20.91% (-1.48%) [Q4]
4% less funds holding
Funds holding: 742 [Q3] → 710 (-32) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 279
15% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 11 (-2) [Q4]
16% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 90
22% less capital invested
Capital invested by funds: $16.4B [Q3] → $12.8B (-$3.61B) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$65
19%
upside
Avg. target
$65
19%
upside
High target
$65
19%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Goldman Sachs James Quigley 0 / 0 met price target | 19%upside $65 | Neutral Initiated | 21 Mar 2025 |
Financial journalist opinion
Based on 23 articles about SNY published over the past 30 days
Neutral
Zacks Investment Research
10 hours ago
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
Positive
Benzinga
10 hours ago
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
Neutral
GlobeNewsWire
21 hours ago
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).
Negative
CNBC Television
2 days ago
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Positive
Zacks Investment Research
2 days ago
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Neutral
GlobeNewsWire
6 days ago
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia Paris, March 28, 2025. The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without factor VIII or IX inhibitors.
Positive
Reuters
6 days ago
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
Neutral
Seeking Alpha
6 days ago
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will discover whether Sanofi or AbbVie is a more promising stock in the long term.
Neutral
GlobeNewsWire
6 days ago
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.
Neutral
Zacks Investment Research
1 week ago
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
Charts implemented using Lightweight Charts™